Sign Up to like & get
recommendations!
0
Published in 2017 at "Journal of Molecular Modeling"
DOI: 10.1007/s00894-017-3314-z
Abstract: AbstractROS1 fusion kinase—highly expressed in a variety of human cancers—has emerged as an important and attractive target for anticancer drug design. Crizotinib, a well-known drug approved by the FDA as an ALK inhibitor to treat…
read more here.
Keywords:
molecular dynamics;
crizotinib;
l2026m g2032r;
resistance ... See more keywords